Efficacy and safety of Bacillus Calmette Guerin (BCG) vaccine and Purified protein derivative (PPD)in treatment of viral warts
Phase 4
- Conditions
- Health Condition 1: null- Multiple viral warts
- Registration Number
- CTRI/2014/12/005244
- Lead Sponsor
- Medical College Kolkata
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Open to Recruitment
- Sex
- Not specified
- Target Recruitment
- 60
Inclusion Criteria
i.Male or female patients between 18 and 65 years of age (both inclusive)
ii.Multiple viral warts (number > 10)
iii.Patients who give their informed consent
Exclusion Criteria
i.Pregnant or lactating women
ii.Any evidence of immunosuppression (egg HIV infection, Organ transplantation, long term steroid use etc.)
iii.Any other systemic disease (egg liver, kidney disorder)
iv.Patients not giving their informed consent
v.Presence of mucosal wart(s)
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method umber of wartsTimepoint: Baseline, 1, 2, 3, 4, 5, 6th month. <br/ ><br>Every patient will be given treatment for 3 months (either BCG or PPD according to randomization) at monthly intervals. They will be followed up for the next 3 months, total study duration of 6 months.
- Secondary Outcome Measures
Name Time Method Serum for Liver Function Test, urea, creatinine, Hemoglobin, Total count, Differential Count, Erythrocyte Sedimentation RateTimepoint: Screening visit, 3rd month visit